<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284504</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-19588</org_study_id>
    <secondary_id>SU-10182010-7110</secondary_id>
    <secondary_id>COL0001</secondary_id>
    <nct_id>NCT01284504</nct_id>
  </id_info>
  <brief_title>Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer</brief_title>
  <official_title>The Effect Of Celecoxib On The Perioperative Inflammatory Response In Colon Cancer Patients - A Double-Blind Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study aims to investigate how the administration of a drug known to reduce
      inflammation in humans, Celecoxib, will effect the peri-operative inflammatory response of a
      patient undergoing primary tumor resection surgery for colon cancer. The proposed project is
      an exploratory study, and will use data from blood samples and tumor samples to attempt to
      elucidate the immune and inflammatory response in colon cancer patients undergoing primary
      resection of their tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is the first to assess the perioperative time course of systemic inflammation and
      immunity in colon cancer patients and evaluate the effect of anti-inflammatory treatment with
      celecoxib on this response. In addition, evaluation of the effect of short-term preoperative
      administration of celecoxib on tumor immunogenicity will help us to understand how
      tumor-enhancing inflammation and anti-tumor immunity can be differentially affected by COX-2
      inhibitors. The knowledge gained as a result of this research will help us to set up the
      infrastructure for a method to monitor the immunoinflammatory status of colon cancer patients
      with a longer term goal of designing interventions to suppress tumor-enhancing inflammation
      and vitalize anti-tumor immunity in the perioperative period. The long-term objective is to
      use these novel tools in order to improve cancer-specific survival in patients with colon
      cancer after primary tumor resection.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual rate; the only participant withdrew after signing consent
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Sample - Analyzed for TCR Repertoire and Global Transcription Profiling</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Samples Taken Before Initiation of Study, Day of Surgery, Days 1 and 3 Post-op, and 30 Days Post-op. Analyzed for 50 Serum Cytokines, Cell-specific Gene Expression, and TCR Repertoire.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surveys to Evaluate Patient Pain, Fatigue, and Quality of Recovery, Recorded From Day of Surgery to 30 Days Post-op.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celecoxib, 200 mg tab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, tab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>200 mg tablet oral</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
    <other_name>Celebra</other_name>
    <other_name>Onsenal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo, tab</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Colon cancer patients with no evidence of metastasis in distant organs (i.e., TNM stage
        I-III), who are

          -  between 18 and 75 years old,

          -  have a body mass index (BMI) between 18 and 35 kg/m^2,

          -  and are eligible for laparoscopically-assisted colectomy for primary tumor resection.

          -  Patients must have the ability to understand and the willingness to sign a written
             informed consent document.

        Exclusion Criteria:

        - A history of allergic-type reactions to celecoxib or sulphonamides,

          -  a history of asthma, skin reactions or other allergic reactions to aspirin or other
             NSAIDs,

          -  a history of thromboembolic event (cerebrovascular accident, transient ischemic
             attack,

          -  unstable angina, myocardial infarction, deep vein thrombosis, or pulmonary embolism),

          -  renal insufficiency (defined by a serum creatinine level &gt; 1.5 mg/dL or blood urea
             nitrogen level &gt; 22 mg/dL),

          -  active gastrointestinal bleeding in the 60 days before surgery,

          -  alcohol or drug abuse, and

          -  previous chemotherapy or abdominal/pelvic radiation therapy.

          -  After randomization, other exclusion criteria will include a surgical procedure longer
             than 6 h, inability to extubate the trachea within 4 h after operation, evidence of a
             new postoperative myocardial infarction, abnormal postoperative mental status or any
             new neurologic deficit, significant postoperative bleeding (with a hemoglobin level &lt;
             7.5 g/dL), requiring blood transfusion, or a urine output of less than 30 mL/h.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Doufas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <results_first_submitted>October 15, 2016</results_first_submitted>
  <results_first_submitted_qc>October 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2016</results_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Anthony Doufas</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1 patient was consented but withdrew before treatment assignment (randomization), none were treated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Celocoxib</title>
          <description>Celecoxib: 200 mg tablet oral</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Celecoxib</title>
          <description>Celecoxib, 200 mg tab
Celecoxib: 200 mg tablet oral</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo, tab
placebo: Placebo, tab</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Sample - Analyzed for TCR Repertoire and Global Transcription Profiling</title>
        <time_frame>2 years</time_frame>
        <population>One patient was accrued and withdrawn after signing consent; none were treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Celocoxib</title>
            <description>Celecoxib: 200 mg tablet oral</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Sample - Analyzed for TCR Repertoire and Global Transcription Profiling</title>
          <population>One patient was accrued and withdrawn after signing consent; none were treated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Samples Taken Before Initiation of Study, Day of Surgery, Days 1 and 3 Post-op, and 30 Days Post-op. Analyzed for 50 Serum Cytokines, Cell-specific Gene Expression, and TCR Repertoire.</title>
        <time_frame>30 days</time_frame>
        <population>One patient was accrued and withdrawn after signing consent; none were treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Celocoxib</title>
            <description>Celecoxib: 200 mg tablet oral</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Samples Taken Before Initiation of Study, Day of Surgery, Days 1 and 3 Post-op, and 30 Days Post-op. Analyzed for 50 Serum Cytokines, Cell-specific Gene Expression, and TCR Repertoire.</title>
          <population>One patient was accrued and withdrawn after signing consent; none were treated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surveys to Evaluate Patient Pain, Fatigue, and Quality of Recovery, Recorded From Day of Surgery to 30 Days Post-op.</title>
        <time_frame>30 days</time_frame>
        <population>One patient was accrued and withdrawn after signing consent; none were treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Celocoxib</title>
            <description>Celecoxib: 200 mg tablet oral</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Surveys to Evaluate Patient Pain, Fatigue, and Quality of Recovery, Recorded From Day of Surgery to 30 Days Post-op.</title>
          <population>One patient was accrued and withdrawn after signing consent; none were treated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Celecoxib</title>
          <description>Celecoxib, 200 mg tab
Celecoxib: 200 mg tablet oral</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo, tab
placebo: Placebo, tab</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anthony Doufas, MD, PhD</name_or_title>
      <organization>Stanford University</organization>
      <phone>1-650-498-7699</phone>
      <email>agdoufas@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

